| Title |
New and Developing Drugs for the Treatment of Neuropathic Pain in Diabetes
|
|---|---|
| Published in |
Current Diabetes Reports, June 2013
|
| DOI | 10.1007/s11892-013-0396-6 |
| Pubmed ID | |
| Authors |
Roy Freeman |
| Abstract |
A number of agents from diverse pharmacological classes are used to treat neuropathic pain associated with diabetic peripheral neuropathy. Only three of these have regulatory approval for this indication in the U.S. In this focused article, I will discuss selected drugs, newly approved or in development, to treat neuropathic pain in patients with diabetic neuropathy. These will include agonists and antagonists of the transient receptor potential channels, a family of receptor proteins that play a role in the transduction of physical stress; sodium channel isoform specific antagonists; a recently approved dual-action opioid receptor agonist-norepinephrine reuptake inhibitor; gene therapy for neuropathic pain; and anti-nerve growth factor molecules. Mechanisms of action, preclinical supporting data, clinical trial evidence, and adverse effects will be reviewed. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 33% |
| United States | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 4% |
| Unknown | 49 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 14% |
| Student > Master | 6 | 12% |
| Student > Bachelor | 6 | 12% |
| Student > Ph. D. Student | 5 | 10% |
| Student > Doctoral Student | 3 | 6% |
| Other | 7 | 14% |
| Unknown | 17 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 22% |
| Agricultural and Biological Sciences | 5 | 10% |
| Biochemistry, Genetics and Molecular Biology | 4 | 8% |
| Neuroscience | 3 | 6% |
| Nursing and Health Professions | 3 | 6% |
| Other | 11 | 22% |
| Unknown | 14 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 June 2013.
All research outputs
#13,038,182
of 22,712,476 outputs
Outputs from Current Diabetes Reports
#522
of 1,004 outputs
Outputs of similar age
#101,751
of 197,681 outputs
Outputs of similar age from Current Diabetes Reports
#2
of 8 outputs
Altmetric has tracked 22,712,476 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,004 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.0. This one is in the 47th percentile – i.e., 47% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 197,681 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.